Get the Stockscreener App
93.35
1.46%
-1.38
After Hours:
93.50
0.15
+0.16%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $93.35, with a volume of 10.90M.
It is down -1.46% in the last 24 hours and up +8.96% over the past month.
See More
Previous Close:
$94.73
Open:
$94.07
24h Volume:
10.90M
Relative Volume:
0.83
Market Cap:
$251.88B
Revenue:
$64.17B
Net Income/Loss:
$17.12B
P/E Ratio:
13.87
EPS:
6.73
Net Cash Flow:
$18.10B
1W Performance:
+0.17%
1M Performance:
+8.96%
6M Performance:
-19.00%
1Y Performance:
-23.90%
1-Day Range:
$92.86
$94.40
1-Week Range:
$91.78
$97.37
52-Week Range:
$81.04
$134.63
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
93.35 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
|
LLY
Lilly Eli Co
|
821.86 | 781.10B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
212.06 | 374.36B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.85 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
74.79 | 332.00B | 42.09B | 14.65B | 10.11B | 3.2833 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck & Co., Inc. (NYSE:MRK) Receives $116.39 Consensus Target Price from Analysts - Defense World
Merck & Co.’s SWOT analysis: pharma giant faces challenges amid keytruda dominance - Investing.com
How Do Investors Really Feel About Merck & Co? - Benzinga
ACTG Presents Study at CROI Demonstrating Potential of CMV-specific Antiviral Inhibitor to Improve Aging-Related Outcomes among People Living with HIV and CMV (Cytomegalovirus) - GlobeNewswire Inc.
Why Merck & Co., Inc. (MRK) is the Best Pharma Stock to Buy According to Hedge Funds - Insider Monkey
Merck's Investigational Two-Drug Regimen Maintained HIV-1 Suppression in Late-Stage Trials - Marketscreener.com
Merck: new treatment option for HIV -March 12, 2025 at 12:16 pm EDT - Marketscreener.com
Merck & Co., Inc. (MRK): Among Dobermans of the Dow to Buy - Insider Monkey
Anti-Inflammatory Therapeutics Market to Reach $125.55 Billion by 2028 | Merck & Co., Inc., GlaxoSmithKline - EIN News
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Merck & Co., Inc. to Contact the Firm Today! - Markets Insider
Class Action Filed Against Merck & Co., Inc. (MRK)April 14, 2025 Deadline to JoinContact Levi & Korsinsky - PR Newswire
Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsMRK - Stockhouse Publishing
Merck scores victory in Gardasil lawsuits as judge questions evidence - Seeking Alpha
Merck prevails in Gardasil safety litigation -March 11, 2025 at 04:40 pm EDT - Marketscreener.com
Merck prevails in Gardasil safety litigation - Reuters
Merck prevails in Gardasil safety litigation -March 11, 2025 at 04:23 pm EDT - Marketscreener.com
2025-03-11 | Merck & Co., Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationMRK | NYSE:MRK | Press Release - Stockhouse Publishing
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
Merck opens $1 billion vaccine manufacturing plant, expanding Durham site - WRAL News
Merck Injects $1 Billion To Expand Vaccine Production In US - Benzinga
Merck opens $1B vaccine production facility (updated) - NJBIZ
Merck opens vaccine plant in North Carolina -March 11, 2025 at 10:20 am EDT - Marketscreener.com
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
Corrected: Merck opens billion-dollar US facility to make Gardasil - Endpoints News
Merck launches new $1B vaccine manufacturing plant in U.S. - Seeking Alpha
Merck opens vaccine manufacturing facility in North Carolina -March 11, 2025 at 06:52 am EDT - Marketscreener.com
Merck Unveils New Facility To Increase Vaccine Production Capacity -March 11, 2025 at 06:47 am EDT - Marketscreener.com
Employees of Merck & Co. from 2008 to 2024 - Statista
Merck Unveils New Facility to Increase Vaccine Production Capacity - Business Wire
Levi & Korsinsky Reminds Merck & Co., Inc. Investors of the - GlobeNewswire
Merck & Co. (MRK): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now - Insider Monkey
Sterile Filtration Market Is Booming Worldwide 2025-2032 | 3M, - openPR
Rep. Jefferson Shreve Purchases Shares of Merck & Co., Inc. (NYSE:MRK) - Defense World
Shareholders that lost money on Merck & Co., Inc.(MRK) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
2025-03-10 | Shareholders that lost money on Merck & Co., Inc.(MRK) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NYSE:MRK | Press Release - Stockhouse Publishing
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
Merck & Co. (MRK): One of the Most Undervalued US Stocks to Buy According to Hedge Funds - MSN
Shareholders of Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsMRK - Stockhouse Publishing
MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - Morningstar
Merck & Co Unusual Options Activity For March 10 - Benzinga
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein - GlobeNewswire
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck & ... - Bluefield Daily Telegraph
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Merck & Co., Inc.(MRK) Shareholders - PR Newswire
Is Merck & Co., Inc. (MRK) the Most Undervalued High Quality Stock to Buy According to Analysts? - Insider Monkey
Merck & Co., Inc. (MRK) Among The Best Cheap Dividend Stock To Buy Right Now - Insider Monkey
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Merck & Co., Inc. (NYSE:MRK) - Defense World
Ophthalmology - Merck
Merck & Co., Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationMRK - PR Newswire
10 Most Undervalued High Quality Stocks to Buy According to Analysts - Insider Monkey
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):